Literature DB >> 22648782

Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells.

Yuntao Zhang1, Yong Wang, Jianlin Yuan, Weijun Qin, Fei Liu, Fuli Wang, Geng Zhang, Xiaojian Yang.   

Abstract

Recent studies have indicated that Toll-like receptors (TLRs) are implicated in the development of chemoresistance in cancer cells. TLR4 has been shown to be highly expressed in prostate cancer cells and contributes to tumor cell survival and invasion. In this study, we aimed to investigate the role of TLR4 signaling in the chemoresistance of prostate cancer cells. We showed that ligation of TLR4 with lipopolysaccharide (LPS) abrogated docetaxel-induced growth suppression in PC-3 prostate cancer cells, with an increase in the half-maximal inhibitory concentration. Downregulation of TLR4 using small-interference RNA sensitized PC-3 cells to docetaxel-induced apoptosis as determined by annexin V staining and poly (ADP-ribose) polymerase cleavage, which was coupled with increased Bax expression and decreased Bcl-2. TLR4 ligation resulted in a marked increase in the phosphorylation of phosphatidylinositol 3-kinase (PI3-K) and Akt. The pretreatment with a PI3-K inhibitor LY294002 reduced LPS-mediated resistance to docetaxel, significantly decreasing the viability of PC-3 cells. Our data show that TLR4 ligation contributes to the chemosensitivity of prostate cancer cells, which at least partially involves the activation of the PI3-K/Akt pathway. Therefore, TLR4 signaling may represent a promising target for the improvement of chemotherapeutic efficacy in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22648782     DOI: 10.1007/s10565-012-9221-2

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  12 in total

1.  A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.

Authors:  Jung Hun Oh; Joseph O Deasy
Journal:  Brief Bioinform       Date:  2015-07-27       Impact factor: 11.622

2.  Topographical changes in extracellular matrix: Activation of TLR4 signaling and solid tumor progression.

Authors:  Rhiannon M Kelsh; Paula J McKeown-Longo
Journal:  Trends Cancer Res       Date:  2013-01-01

3.  Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.

Authors:  Huarong Huang; Ting Liu; Junxi Guo; Lin Yu; Xiaofeng Wu; Yan He; Dongli Li; Junlei Liu; Kun Zhang; Xi Zheng; Susan Goodin
Journal:  Bioorg Med Chem Lett       Date:  2017-04-17       Impact factor: 2.823

4.  Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.

Authors:  Matthias Saar; Hongjuan Zhao; Rosalie Nolley; Sarah R Young; Ilsa Coleman; Peter S Nelson; Robert L Vessella; Donna M Peehl
Journal:  Cancer Lett       Date:  2014-07-03       Impact factor: 8.679

5.  TLR4 is a novel determinant of the response to paclitaxel in breast cancer.

Authors:  Sandeep Rajput; Lisa D Volk-Draper; Sophia Ran
Journal:  Mol Cancer Ther       Date:  2013-05-29       Impact factor: 6.261

6.  Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance.

Authors:  Derek W Edwardson; Justin Boudreau; Jonathan Mapletoft; Carita Lanner; A Thomas Kovala; Amadeo M Parissenti
Journal:  PLoS One       Date:  2017-09-15       Impact factor: 3.240

7.  TLR4 increases the stemness and is highly expressed in relapsed human hepatocellular carcinoma.

Authors:  Shuang Zhou; Renle Du; Zhenglu Wang; Wenzhi Shen; Ruifang Gao; Shan Jiang; Yan Fang; Yuzhi Shi; Antao Chang; Lei Liu; Chenghu Liu; Na Li; Rong Xiang
Journal:  Cancer Med       Date:  2019-04-08       Impact factor: 4.452

Review 8.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

Review 9.  Toll-like receptors and prostate cancer.

Authors:  Shu Zhao; Yifan Zhang; Qingyuan Zhang; Fen Wang; Dekai Zhang
Journal:  Front Immunol       Date:  2014-07-23       Impact factor: 7.561

Review 10.  The role of toll-like receptor 4 in tumor microenvironment.

Authors:  Jing Li; Fan Yang; Feng Wei; Xiubao Ren
Journal:  Oncotarget       Date:  2017-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.